Fused heterocyclic compound
US9745325B2 · kind B2 · utility
1Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2015 |
| Grant date | Aug 29, 2017 |
| Priority date | — |
| Expiry date | Apr 16, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I)(wherein the symbols are as defined in the description) or a salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.